A Phase 3 clinical trial of the ORX-TP eye insert made by Ocular Therapeutix (NSDQ:OCUL) failed to meet the primary endpoint of significant superiority in the reduction of intraocular pressure.
OTX-TP is an intracanalicular insert that delivers a preservative-free formulation of travoprost to reduce intraocular pressure.
The randomized, double-blind, placebo-controlled clinical trial took place across more than 50 sites with 554 subjects who had open-angle glaucoma or ocular hypertension in the full analysis set population.
Get the full story on our sister site, Drug Delivery Business.